• Home
  • The Effect of Magnesium Oxide Nanoparticles on Oxidative Stress in a Parkinson's Model of Male Rats

Share To

Article Url


Manuscript ID : ASCIJ-2205-1392 (R1) Visit : 242 Page: 97 - 109

10.22034/ascij.2022.1958259.1392

Article Type: Original Research

The Effect of Magnesium Oxide Nanoparticles on Oxidative Stress in a Parkinson's Model of Male Rats

Subject Areas : Journal of Animal Biology

Hoda Ghorbani moghaddam 1 , Akram Eidi 2 , Pejman Mortazavi 3 , Shahrbanoo Oryan 4

1 - Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
2 - Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
3 - Department of Veterinary, Science and Research Branch, Islamic Azad University, Tehran, Iran
4 - Department of Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran

Received: 2022-05-18 Accepted : 2022-07-06 Published : 2023-02-20

Keywords: Oxidative stress, Magnesium oxide nanoparticles, Parkinson disease, 6-Hydroxy dopamine,

Abstract :

Since limited studies have evaluated the antioxidant effects of magnesium oxide nanoparticles on Parkinson's disease, the aim of this study is to investigate the effect of magnesium oxide nanoparticles (MON) on oxidative stress in the Parkinson's model in mice. In this experimental study, 54 adult male rats were divided into nine groups of six, including: healthy control group, parkinsonian control group receiving 6-hydroxydopamine in the lateral ventricle, sham group receiving normal saline and healthy experimental group receiving magnesium oxide nanoparticles in doses of 2.5, 5 and 10 mg/kg and experimental Parkinson's groups that in addition to inducing Parkinson's, received magnesium oxide nanoparticles in doses of 2.5, 5 and 10 mg/kg. Administration of nanoparticles was intraperitoneal for 30 days. After that, oxidative stress parameters MDA, CAT and SOD were measured in the brain tissue. The results of the present study showed that treatment with magnesium oxide nanoparticles significantly reduced the amount of oxidative stress parameters in the brain tissue (p < 0.05). Magnesium oxide nanoparticle treatment in doses of 5 and 10 mg/kg decreased MDA in parkinsonian groups compared to parkinsonian control animals. Also, the treatment of magnesium oxide nanoparticles in doses of 5 and 10 mg/kg in the parkinsonian group caused a significant increase in the activity of SOD and CAT enzymes compared to parkinsonian control animals. As a result, it can be said that magnesium oxide nanoparticle can play a promising role with its effectiveness in reducing oxidative stress processes in Parkinson's model.

References:

1.    Abdolahzadeh Dashti M., Kesmati,M, Khaje Por L., Najafzadeh Varzi H. 2014. The preventative role of Mgo nanoparticles in amnesia induced by morphine in mouse. Iranian Veterinary Journal, 10(3):55-64.

  1. Actis L., Srinivasan A., Lopez-Ribot JL, Ramasubramanian A.K., Ong J.L. 2015. Effect of silver nanoparticle geometry on methicillin susceptible and resistant Staphylococcus aureus, and osteoblast. viability. Journal of Materials Science: Materials in Medicine, 26(7):215.
    2.
  2. Aebi H. Catalase in vitro. Methods in Enzymology, 105:121-126.
    3.
  3. Archakov 2010. Nano biotechnologies in medicine: Nanodiagnostics and nano drugs. Biomedicical Chemistry, 4(1): 2-14.
    4.
  4. Archakov A.I., Ivanov Y.D. 2007. Analytical nanobiotechnology for medicine diagnostics. Molecular Biosystems, 3:336-342.
    5.
  5. Canepari M. 2019. Dopamine and action potential generation in the axon initial segment. Journal of Physiology, 597(13): 3251-2.
    6.
  6. Cannon J.R., Tapias V., Na H.M., Honick A.S., Drolet R.E. 2009.Greenamyre JT. A highly reproducible rotenone model of Parkinsons disease. Neurobiological Disorders, 34:279 -290.
    7.
  7. Carvalho M.M., Campos F.L. Coimbra B., Pego JM., Rodrigues C., Lima R., et al, 2013. Behavioral characterization of the 6- hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits. Molecular Neurodegeneration, 8:14.
    8.
  8. Choi W.S., Palmiter R.D., Xia Z. 2011. Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson's disease model. Journal of Cell Biology, 192(5):873-882.
    9.
  9. Clark J., Silvaggi J.M., Kiselak T., Zheng K., Clore EL., Dai Y., et al. 2012. Pgc1α overexpression downregulates Pitx3 and increases susceptibility to MPTP toxicity associated with decreased Bdnf. PloS One, 7(11):e48925.
    10.
  10. Cohen A.D. 2006. Role of exercise and GDNF in an animal model of parkinson’s disease: implications for neuroprotection. University of Pittsburgh.
    11.
  11. Dauer W., Przedborski S. 2003. Parkinson's disease: mechanisms and models. Neuron, 39(6):889-909.
    12.
  12. Dionísio P.A., Amaral J.D., Rodrigues C.M.P. 2021. Oxidative stress and regulated cell death in Parkinson’s disease. Ageing Research Reviews, 67:101263.
    13.
  13. Durán N., Silveira CP., Durán M., Martinez DS. 2015. Silver nanoparticle protein corona and toxicity: a mini-review. Journal of Nanobiotechnology, 13(1): 55.
    14.
  14. Gasbarri A., Sulli A., Innocenzi R., Pacitti C., Brioni J.D. 2005. Spatial memory impairment induced by lesion of the mesohippocampal dopaminergic system in the rat. Neuroscience, 74(4):1037-1044.
    15.
  15. Hales K. 2009. Homocysteine is linked to cardiovascular disease, neurological conditions. Plos One, 3:8-14.
    16.
  16. Heckert E.G., Karakoti A.S., Seal S., Self W.T. 2008. The role of ceriumredox state in the SOD mimetic activity of nanoceria. Biomaterials. 29(18):2705-2709.

  17. Heidari A., Yazdanpanah N., and Rezaei 2022. The role of Toll-like receptors and neuroinflammation in Parkinson’s disease. Journal of Neuroinflammation, 19(1): 1-21.
    18.
  18. Hooshmandi Z., Rohani AH., Eidi A., Fatahi Z., Golmanesh L., Sahraei H. 2011. Reduction of metabolic and behavioral signs of acute stress in male Wistar rats by saffron water extract and its constituent safranal. Pharmaceutical Biology, 49(9): 947-954.
    19.
  19. Jayaram, S. and Krishnamurthy, P.T., 2021. Role of microgliosis, oxidative stress and associated neuroinflammation in the pathogenesis of Parkinson's disease: The therapeutic role of Nrf2 activators. Neurochemistry Jnternational, 145:105014.
    20.
  20. Kandel E.R., Aschwurtz J.H., Jessell T.M. 2000. Principle of Natural Science, 4th ed, McGraw-Hill, pp: 862-1275.
    21.
  21. Ko W.C., Wang S.J., Hsiao C.Y., Hung C.T., Hsu Y.J., Chang D.C., Hung C.F. 2022. Pharmacological role of functionalized gold nanoparticles in disease applications. Molecules, 27(5):1551.
    22.
  22. Lin T.K., Liou C.W., Chen S.D., Chuang Y.C., Tiao M.M., Wang P.W., 2009. Mitochondrial dysfunction and biogenesis in the pathogenesis of Parkinson’s disease. Chang Gung Medical Journal, 32(6):589-599.
    23.
  23. Liu B., Dluzen DE. 2007. Oestrogen and nigrostriatal dopaminergic neurodegenteration: animal models and clinical reports of Parkinson's disease. Clinical Experimental Pharmacology and Physiology, 34:65-555.
    24.
  24. Liu G. 2012. Prevention of cognitive deficits in Alzheimer mouse model by elevating brain magnesium. International Conference on Molecular Neurodegeneration, 7(2):1-24.
    25.
  25. Marklund S., Marklund G. 1974. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. EurJBiochem, 47(3):469-474.
    26.
  26. Michael P., Smith Wayne A. 2007. Cass Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson’s disease Neuroscience. 144:1057-1066.
    27.
  27. Moradi F. 2014. Antioxidant effects of magnesium in reducing oxidative stress by injected via an intraperitoneally carbon tetrachloride in the Wistar male adult rats. Armaghane Journal of Medical Sciences Journal (YUMSJ), 19(8):23-33.
    28.
  28. Mura A., Feldon J. 2003. Spatial learning in rats is impaired after degeneration of the nigrostriatal dopaminergic system. Movement Disorders, 18(8):860-871.
    29.
  29. Olsson M., Nikkhah G., Bentlage C. 1995. Akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. Journal of Neurosciences, 15(5 Pt 2): 3863-3875.
    30.
  30. Oyanagi K, Hashimoto T. 2011. Magnesium in Parkinson’s disease: an update in clinical and basic aspects. In: Vink R, Nechifor M, editors. Magnesium in the Central Nervous System [Internet]. Adelaide (AU): University of Adelaide Press.
    31.
  31. Panchanan M., Jayeeta M., Gary L. 2017. Current understanding of the molecular mechanisms in Parkinsons disease targets for potential treatments. Trans Neuro, 6:1-35.
    32.
  32. Paxinos G., Watson C. 2006. The Rat brain in stereotaxic coordinates. 6th ed, New York NY USA Academic Publication, P: 232-239.
    33.
  33. Perier C., Vila M. 2012. Mitochondrial biology and Parkinson’s disease. Cold Spring Harb Perspective Medicine, 2(2): a009332.
    34.
  34. Potashkin J.A., Blume S.R., Runkle N.K. 2010. Limitations of animal models of Parkinson's disease. Parkinson's Disorders, 2011:658083.
    35.
  35. Pourkhalili N., Hosseini A., Nili-Ahmadabadi A. Biochemical and cellular evidence of the benefit of a combination of cerium oxide nanoparticles and selenium to diabetic rats. World Journal of Diabetes, 2:204-210.
    36.
  36. Praveen, T.K., Gangadharappa, H.V., Lila, A.S.A., Moin, A., Mehmood, K., Krishna, K.L., Hussain, T., Alafanan, A., Shakil, S., Rizvi, S.M.D. 2022. April. Inflammation targeted nanomedicines: Patents and applications in cancer therapy. Seminars in Cancer Biology, 9:S1044-9.
    37.
  37. Rahimi A. 2014. Induction of Parkinson’s disease model in rat by rotenone. Journal of Isfahan Medical School, 32(296):1-15.
    38.
  38. Rivas-Arancibia S., Guevara-Guzmán R., Lopez-Vidal Y., Rodríguez-Martínez E., Zanardo-Gomes M., Angoa-Perez M, etal. 2010. Oxidativestress caused by ozone exposure induces loss of brain repair in the hippocampus of adult rats. Toxicological Sciences, 113(1):187-197.
    39.
  39. Ryan C.M., Geckle M. 2000. Why is learning and memory dysfunction in Type 2 diabetes liited to older adults. Diabetes Metabolism Research Reviews, 16:308-315.
    40.
  40. Satoh K. 1978. Serum lipid peroxidation in cerebrovascular disorders determined by a new colorimetric method. Clinica Chimica Acta, 90:37-43.
    41.
  41. Slutsky I., Abumaria N., Wu L.J., Huang C., Zhang L., Li B. 2010. Enhancement of learning and memory by elevating brain magnesium. Neuron, 65(2): 165-177.
    42.
  42. Sun H. 2018. Association of soil selenium, strontium, and magnesium concentrations with Parkinson's disease mortality rates in the USA. Environ Geochem Health. 40(1):349-357.
    43.
  43. Spijker S.  2011. Dissection of Rodent Brain Regions. Neuroproteomics, Humana Press, New York, 317 pp.
    44.
  44. Tansey M.G., Wallings R.L., Houser M.C., Herrick M.K., Keating C.E., Joers V. 2022. Inflammation and immune dysfunction in Parkinson disease. Nature Reviews Immunology, 4:1-17.
    45.
  45. Tiwari P.C., Pal R. The potential role of neuroinflammation and transcription factors in Parkinson disease. Dialogues in Clinical Neuroscience, 19(1):71-80.
    46.
  46. Uppalapati D., Das N.R., Gangwal R.P., Damre M.V., Sangamwar A.T., Sharma S.S. 2014. Neuroprotective Potential of peroxisome proliferator activated receptor-α agonist in cognitive impairment in parkinson’s disease: behavioral, biochemical, and PBPK profile. PPAR Research, 2014:753587.
    47.
  47. Xiong N., Xiong J., Khare G., Chen C., Huang J., Zhao Y. 2011. Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease. PLoS One, 6(6):e20677.
    48.
  48. Young S.W., Stenzel M., Jia-Lin Y. 2016. NanoparticlesiRNA: A potential cancer therapy? Critical reviews in oncology/hematology. 98:159-169.
    49.

 

 

_||_

Related articles

The rights to this website are owned by the Raimag Press Management System.
Copyright © 2021-2024

Home| Login| About Us| Contact Us|
[فارسی] [العربية] [fa] [ar]